Should we quantify insulin resistance in patients with renal disease?

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Cardiovascular disease (CVD) is a leading cause of death in dialysis patients.
• Chronic kidney disease (CKD) is an independent risk factor for CVD, with vascular disease developing before dialysis initiation.
• Insulin resistance (IR) is a significant contributor to the elevated vascular risk observed in CKD patients.

Purpose of the Study:

• To explore the role of insulin resistance (IR) in the pathogenesis of cardiovascular disease (CVD) in chronic kidney disease (CKD) patients.
• To discuss the quantification of IR using methods like the homeostatic model assessment (HOMA) index.
• To review potential interventions targeting IR in the context of CKD.

Main Methods:

• Review of existing literature on CKD, CVD, and insulin resistance.
• Discussion of the homeostatic model assessment (HOMA) technique for quantifying IR.
• Examination of the relationship between CKD, metabolic syndrome features, and IR.

Main Results:

• The HOMA index is a validated, independent predictor of survival in dialysis patients.
• CKD is associated with features of metabolic syndrome and IR, contributing to vascular complications.
• Chronic inflammation and adipose tissue dysfunction in CKD may promote IR.

Conclusions:

• Insulin resistance is a critical factor in the high cardiovascular morbidity and mortality associated with chronic kidney disease.
• The HOMA index offers a valuable tool for assessing IR and predicting outcomes in dialysis patients.
• Further research is needed to systematically evaluate interventions aimed at improving IR in CKD patients.